ArticleBrain, behavior, & immunity - health2026
Association of inflammatory biomarkers during pregnancy and the postpartum period with the risk of postpartum anxiety symptoms.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammation is pivotal in psychiatric pathophysiology, yet evidence linking inflammatory biomarkers to postpartum anxiety (PPA) remains lacking. Methods: We included 14,419 eligible postpartum women and calculated composite inflammatory biomarkers during second and third trimesters and the postpartum period, including platelet-neutrophil product (PPN), systemic inflammatory response index (SIRI) and pan-immune-inflammation value (PIV). PPA symptoms were only assessed by Self-Rating Anxiety Scale (SAS) at 5-8 weeks after childbirth. Propensity score matching (PSM) was performed to minimize confounding bias. Multivariable logistic regression analyses were used to examine the associations of inflammatory biomarkers with risk of PPA symptoms. Model discrimination, calibration, and clinical utility were assessed via the receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Machine learning was applied to strengthen the robustness. Results: After PSM, the final analysis comprised 113 women with PPA symptoms (SAS ≥50) and 113 asymptomatic women (SAS < 50). After confounder adjustment, elevated second-trimester PPN, SII and PIV levels were associated with a reduced risk of PPA symptoms, with adjusted ORs of 0.21 (95% CI: 0.10, 0.45), 0.34 (95% CI: 0.16, 0.72), 0.44 (95% CI: 0.26, 0.75), respectively. Consistent results were observed during third trimester and the postpartum period (all Conclusions: Our findings demonstrated that inflammatory biomarkers were associated with PPA symptoms, emphasizing the potential role of PPN in the pathogenesis and application values of PPA symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.